Worth reading
32Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
100
% (anti-IgE antibody positivity rate in the FPP004X-treated group in Part 2)Wording
Conditional
How definitive the wording is.Preliminary results from the Phase 1 clinical trial of the antibody-inducing peptide “FPP004X”
Subject Entity
FunPep Company Limited (submitting company)
Target Locations / Products
Antibody-inducing peptide “FPP004X” / Cohort 4 (Japanese cedar pollen) using a pollen exposure chamber
This disclosure07/27/2026
Amount of Impact on Business Performance
Impact amount: not disclosed (no impact on results for the fiscal year ending December 2026)
Impact on Earnings Forecast
There is no impact on results for the fiscal year ending December 2026.
Outlook
Discussions will continue with Shionogi & Co., Ltd. regarding the development policy for FPP004X.
| Item | Details |
|---|---|
| Event name | Preliminary results from the Phase 1 clinical trial of the antibody-inducing peptide “FPP004X” |
| Subject Entity | FunPep Company Limited (submitting company) |
| Target Locations / Products | Antibody-inducing peptide “FPP004X” / Cohort 4 (Japanese cedar pollen) using a pollen exposure chamber |
| Amount of Impact on Business Performance | Impact amount: not disclosed (no impact on results for the fiscal year ending December 2026) |
| Impact on Earnings Forecast | There is no impact on results for the fiscal year ending December 2026. |
| Outlook | Discussions will continue with Shionogi & Co., Ltd. regarding the development policy for FPP004X. |
Items this document does not state (19)
Date of occurrenceDate recognized / date notice receivedCauseAccounting period in which recognizedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the preliminary results from the Phase 1 clinical trial. No reason is given for the lack of improvement in symptom scores.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.